Ann: Combined FOXFIRE Study Data Presented at ASCO Annual Meeting, page-65

The p values for HCV and HBV in HCC were > 0.1, so didn't reach significance. For the mCRC there is a clear subgroup to chase. Either they can gather enough evidence from FOXFIRE plus any other sources (maybe RESIN), or they decide extra data is needed to get a broad recommendation. This might come down to biomarker studies from SIRFLOX/FOXFIRE to try and find a better correlate than side, or at worst might mean another trial to better focus on this subgroup and get enough patients. The error bars were quite wide for the hazard ratio. How to treat these patients in the meantime? If the data at WCGIC is convincing you may find some early adopters using it in this setting, but what we really want is a big fat recommendation for use. Hope the data is good enough